PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
All content for PeerVoice Clinical Pharmacology Video is the property of PeerVoice and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
PeerVoice Clinical Pharmacology Video
1 hour 1 minute 14 seconds
2 months ago
Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
Visit https://www.peervoice.com/ZUC860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC”, participants will be able to: Utilise appropriate diagnostic technologies to overcome challenges in accurately characterising molecular alterations in patients with NTRK fusion-positive and HER2-mutant advanced NSCLC; Differentiate between precision oncology therapies used in patients’ management of NTRK fusion-positive advanced NSCLC; Distinguish between the study populations of clinical trials examining emerging targeted therapies in patients with advanced NSCLC harbouring HER2-activating mutations from studies examining other HER2 aberrations; and Describe the recent data and clinical significance associated with trials examining emerging targeted therapies in patients with advanced NSCLC harbouring HER2-activating mutations.
PeerVoice Clinical Pharmacology Video
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
